Policy Focus On Drug Cost-Effectiveness Studies Could Take Heat Off Devices
This article was originally published in The Gray Sheet
Executive Summary
Medical devices may enjoy a temporary reprieve from policymakers' increasing calls for rigorous cost-effectiveness analyses, with the current spotlight directed on pharmaceuticals